Karolinska Development AB
Karolinska Development’s Extraordinary General Meeting

DGAP-News: Karolinska Development AB

04.12.2014 / 16:48

---------------------------------------------------------------------

STOCKHOLM - December 4, 2014. At the Extraordinary General Meeting of
Karolinska Development AB held today, the following resolutions were passed, in
accordance with the presented proposals: 

Rights issue of convertible bonds: It was resolved that the company shall raise
a convertible loan with a nominal amount not exceeding SEK 227,455,941.72
through a rights issue of convertible bonds. The loan carries an annual
interest rate of eight (8) per cent and has a term of five (5) years. The
conversion rate is SEK 22. 

Directed issue of convertible bonds: It was resolved that the company shall
raise a convertible loan with a nominal amount not exceeding SEK 172,858,294.11
through a directed issue of convertible bonds to Chia Tai Resources Limited and
Sino Biopharmaceuticals Limited, both of which belong the Asian Thai Charoen
Pokphand Group (CP Group). The same terms and conditions as for the convertible
bonds issued with pre-emption rights for the company's shareholders shall apply
on the convertible bonds in the directed issue. 

Performance based share incentive program 2014 II (PSP 2014 II): It was
resolved to adopt the board's proposal for a Performance Share Program 2014 II
(PSP 2014 II). 



Complete information regarding each resolution of the Extraordinary General
Meeting can be found on Karolinska Development's website:
www.karolinskadevelopment.com. 



For further information, please contact:
Bruno Lucidi, CEO, Karolinska Development AB
Phone: +46 (0) 72 245 9892, e-mail: Bruno.lucidi@karolinskadevelopment.com







TO THE EDITORS

About Karolinska Development AB
Karolinska Development aims to create value for patients, researchers,
investors and society by developing innovations from world class science into
differentiated products that can be partnered. The business model is to: SELECT
the most commercially attractive medical innovations that can potentially
satisfy unmet medical needs; DEVELOP innovations to the stage where the
greatest return on investment can be achieved; and COMMERCIALIZE the
innovations through the sale of companies or out-licensing of products. An
exclusive deal flow agreement with Karolinska Institutet Innovations AB, along
with other cooperation agreements with leading universities, delivers a
continuous flow of innovations. For more information, please visit
www.karolinskadevelopment.com. 

Karolinska Development is listed on NASDAQ OMX (KDEV). Karolinska Development
may be required to disclose the information provided herein pursuant to the
Securities Markets Act. 





IMPORTANT INFORMATION
This press release is not an offer to sell or a solicitation of any offer to
buy any securities issued by Karolinska Development AB (publ) (the 'Company')
in any jurisdiction. 

Any securities referred to herein have not been and will not be registered
under the U.S. Securities Act of 1933, as amended (the 'Securities Act'), and
may not be offered or sold in the United States absent registration or an
exemption from registration under the Securities Act.  There is no intention to
register any securities referred to herein in the United States or to make a
public offering of the securities in the United States. 

In the United Kingdom, this announcement and any other materials in relation to
the securities described herein is only being distributed to, and is only
directed at, and any investment or investment activity to which this
announcement relates is available only to, and will be engaged in only with,
'qualified investors' (as defined in section 86(7) of the Financial Services
and Markets Act 2000) and who are (i) persons having professional experience in
matters relating to investments who fall within the definition of 'investment
professionals' in Article 19(5) of the Financial Services and Markets Act 2000
(Financial Promotion) Order 2005 (the 'Order'); or (ii) high net worth entities
falling within Article 49(2)(a) to (d) of the Order (all such persons together
being referred to as 'relevant persons').  Persons who are not relevant persons
should not take any action on the basis of this announcement and should not act
or rely on it.
News Source: NASDAQ OMX



---------------------------------------------------------------------

04.12.2014 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


Language:    English                    
Company:     Karolinska Development AB  
 
 
             Sweden                     
ISIN:        SE0002190926               
 
 
End of News    DGAP News-Service  
---------------------------------------------------------------------  
302633 04.12.2014